HEALTHSTORY 551· AUGUST 3, 2026

California Supreme Court rules Gilead Sciences has no legal duty to fast-track a safer HIV drug

Pharmaceutical companies do not owe patients a legal duty to speed up development of a safer drug simply because a less safe version is already on the market. That concept, called a "duty to innovate," was at the center of a case brought…

NDNewsDialy Desk2 MIN READ

SOURCE

statnews.com

← PREVIOUS STORY 550BlackRock launches two tokenized money market funds for stablecoin reserve managers NEXT STORY 552 →Amazon gets $600 million back on Trump-era tariffs and will share some of it with customers

Keep reading

More from the desk.

04HEALTH

AstraZeneca's breast cancer pill camizestrant fails first-line trial

A breast cancer drug failed its largest clinical test, a result that could limit how widely the medicine is prescribed. First-line therapy is the term for the initial drug doctors try after a patient's cancer advances, before other options…

health2 MIN

21HEALTH

Federal health officials give states a clearer tool for Medicaid work exemptions

States can now sort Medicaid recipients into health-severity tiers when deciding who is too ill to work or volunteer, under guidance released this week by the Centers for Medicare and Medicaid Services. Medical frailty, in plain terms, is…

health2 MIN

26HEALTH

Venkat Krishnamurthy named chief scientific officer of Alloy Therapeutics' genetic medicines division

The scientific leader of a genetic medicines division has changed. Genetic medicines, in plain terms, is the field of therapies that act on DNA or RNA to treat disease at its source. Alloy Therapeutics is the company gaining a new leader…

health1 MIN

Tomorrow · 06:00

Start tomorrow already ahead.

Five stories, a two-minute read, zero noise — the world before your first coffee.

Get the 6AM brief Back to the desk